Literature DB >> 16451078

Synthesis of cyclopentenyl carbocyclic nucleosides as potential antiviral agents against orthopoxviruses and SARS.

Jong Hyun Cho1, Dale L Bernard, Robert W Sidwell, Earl R Kern, Chung K Chu.   

Abstract

A practical and convenient methodology for the synthesis of chiral cyclopentenol derivative (+)-12a has been developed as the key intermediate that was utilized for the synthesis of biologically active carbocyclic nucleosides. The selective protection of allylic hydroxyl group followed by the ring-closing metathesis (RCM) reaction with Grubbs catalysts provided (+)-12a on a 10 g scale with 52% overall yield from D-ribose (4). The key intermediate (+)-12a was utilized for the synthesis of unnatural five-membered ring heterocyclic carbocyclic nucleosides. The newly synthesized 1,2,3-triazole analogue (17c) exhibited potent antiviral activity (EC(50) 0.4 microM) against vaccinia virus and moderate activities (EC(50) 39 microM) against cowpox virus and severe acute respiratory syndrome coronavirus (SARSCoV) (EC(50) 47 microM). The 1,2,4-triazole analogue (17a) also exhibited moderate antiviral activity (EC(50) 21 microM) against SARSCoV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16451078     DOI: 10.1021/jm0509750

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  Stereochemical and regiochemical trends in the selective detection of saccharides.

Authors:  Shan Jiang; Jorge O Escobedo; Kyu Kwang Kim; Onur Alptürk; George K Samoei; Sayo O Fakayode; Isiah M Warner; Oleksandr Rusin; Robert M Strongin
Journal:  J Am Chem Soc       Date:  2006-09-20       Impact factor: 15.419

2.  Synthesis and antiviral activities of new acyclic and "double-headed" nucleoside analogues.

Authors:  Xinying Zhang; Adel Amer; Xuesen Fan; Jan Balzarini; Johan Neyts; Erik De Clercq; Mark Prichard; Earl Kern; Paul F Torrence
Journal:  Bioorg Chem       Date:  2006-12-02       Impact factor: 5.275

3.  Synthesis of cyclopentanyl carbocyclic 5-fluorocytosine ((-)-5-fluorocarbodine) using a facially selective hydrogenation approach.

Authors:  Jong Hyun Cho; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  J Org Chem       Date:  2012-12-26       Impact factor: 4.354

4.  Efficient synthesis of exo-N-carbamoyl nucleosides: application to the synthesis of phosphoramidate prodrugs.

Authors:  Jong Hyun Cho; Steven J Coats; Raymond F Schinazi
Journal:  Org Lett       Date:  2012-05-03       Impact factor: 6.005

5.  Synthesis of carbocyclic nucleoside analogs with five-membered heterocyclic nucleobases.

Authors:  Jong Hyun Cho; Steven J Coats; Raymond F Schinazi
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

6.  6'-Oxa Analogs of S-Adenosylhomocysteine.

Authors:  Weikuan Li; Wei Ye; Stewart W Schneller
Journal:  Tetrahedron       Date:  2012-01-07       Impact factor: 2.457

7.  Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.

Authors:  Hyo-Joong Kim; Ashoke Sharon; Chandralata Bal; Jianing Wang; Madhan Allu; Zhuhui Huang; Michael G Murray; Leda Bassit; Raymond F Schinazi; Brent Korba; Chung K Chu
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

8.  Concerning the selective protection of (Z)-1,5-syn-ene-diols and (E)-1,5-anti-ene-diols as allylic triethylsilyl ethers.

Authors:  Jacqueline D Hicks; Chan Woo Huh; Ashley D Legg; William R Roush
Journal:  Org Lett       Date:  2007-11-21       Impact factor: 6.005

Review 9.  Cu(I)-catalyzed Huisgen azide-alkyne 1,3-dipolar cycloaddition reaction in nucleoside, nucleotide, and oligonucleotide chemistry.

Authors:  Franck Amblard; Jong Hyun Cho; Raymond F Schinazi
Journal:  Chem Rev       Date:  2009-09       Impact factor: 60.622

Review 10.  Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection.

Authors:  Vincent C C Cheng; Susanna K P Lau; Patrick C Y Woo; Kwok Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.